1. Real world effectiveness of oral semaglutide: Focus on patients with type 2 diabetes older than 75 years.
- Author
-
Baronti W, Lencioni C, Occhipinti M, Nicolucci A, and Cianni GD
- Subjects
- Humans, Aged, Male, Female, Aged, 80 and over, Administration, Oral, Treatment Outcome, Middle Aged, Blood Glucose drug effects, Blood Glucose metabolism, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 blood, Glucagon-Like Peptides therapeutic use, Glucagon-Like Peptides administration & dosage, Hypoglycemic Agents therapeutic use, Hypoglycemic Agents administration & dosage, Glycated Hemoglobin metabolism, Glycated Hemoglobin analysis
- Abstract
Aim: Data on the efficacy of oral semaglutide (OS) in elderly patients with type 2 diabetes are still lacking. This study evaluates the effectiveness of OS in a real world setting with a large ≥75 year old population., Methods: This study includes all type 2 diabetic patients who started OS between October 2021 and December 2023 in seven diabetes centers. Data were collected at baseline, 6 (T6) and 12 (T12) months. Effectiveness measures were assessed on the total sample and by patient age (<65, 65-75, >75 years)., Results: Overall 1824 patients started OS, of those 18.7 % were over 75 years (>75 yr). OS resulted in a significant reduction in rate of patients using sulphonylureas, rapid and basal insulin therapy, HbA1c reduced by 0.87 % at T6 and at T12 (both p < 0.0001), body weight by 2.78 Kg (p < 0.0001) at T6 and 3.89 Kg (p < 0.0001) at T12. Similarly, >75 yr showed HbA1c reduction at T6 (p < 0.0001) and T12 (p = 0.0003), body weight significantly reduced (p for interaction 0.005) both at T6 (-1.57 Kg; p = 0.0003) and T12 (-2.74 Kg; p < 0.0001)., Conclusion: In our study, OS results efficacy in non-elderly and elderly patients, making it an effective treatment option also for very elderly type 2 diabetic patients., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF